28 March 2023
BerGenBio ASA: BerGenBio to Present at Upcoming Scientific Conferences
– Data on AXL as a therapeutic target in lung cancers to be highlighted at AACR –
– Ph1a/2b 1L STK11m NSCLC trial design to be outlined at ELCC –
BERGEN, Norway, March 28,2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting three posters at two upcoming scientific conferences: ESMO’s European Lung Cancer Congress (ELCC) 2023 and the American Association for Cancer Research (AACR) Annual Meeting 2023.
European Lung Cancer Conference 2023
March 29 – April 1, 2023
Bella Center – Copenhagen, Denmark
Poster Title: Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations (https://cslide.ctimeetingtech.com/elcc23hybrid/attendee/confcal/presentation/list?q=78TiP)
Session Title: Poster Display session (ID 51)
Session Date & Time: Friday March 31, 2023, 12:00 PM – 12:45 PM
Location: Exhibition and Poster area
Presentation Number: 78TiP
American Association for Cancer Research Annual Meeting 2023
April 14 – 19, 2023
Orlando County Convention Center – Orlando, Florida
Poster Title: AXL as a Therapeutic Target in STK11 mutant NSCL (https://www.abstractsonline.com/pp8/#!/10828/presentation/3138)C
Session Title: Combination Immunotherapies 1
Session Date and Time: Monday Apr 17, 2023, 1:30 PM – 5:00 PM
Location: Section 39
Poster Board Number: 18
Abstract Presentation Number: 3245
Poster Title: Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer (https://www.abstractsonline.com/pp8/#!/10828/presentation/1853)
Session Title: DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
Session Date and Time: Wednesday Apr 19, 2023, 9:00 AM – 12:30 PM
Location: Section 18
Poster Board Number: 8
Abstract Presentation Number: 6206
The posters from both conferences will be available on the Company’s website in the Scientific Presentations (https://www.bergenbio.com/investors/presentations/) portion of the Investors section following their presentations.
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Graham Morrell
graham.morrell@bergenbio.com
Media Relations Norway
Jan Lilleby
jl@lillebyfrisch.no
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
